BASF SE's (ETR:BAS) price-to-earnings (or "P/E") ratio of 29.8x might make it look like a sell right now compared to the market in Germany, where around half of the companies have P/E ratios below 22x and even P/E's below 12x are quite common. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's lofty.
With earnings growth that's superior to most other companies of late, BASF has been doing relatively well. The P/E is probably high because investors think this strong earnings performance will continue. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.
Check out our latest analysis for BASF
Does Growth Match The High P/E?
BASF's P/E ratio would be typical for a company that's expected to deliver solid growth, and importantly, perform better than the market.
If we review the last year of earnings growth, the company posted a terrific increase of 85%. Despite this strong recent growth, it's still struggling to catch up as its three-year EPS frustratingly shrank by 63% overall. Therefore, it's fair to say the earnings growth recently has been undesirable for the company.
Turning to the outlook, the next three years should generate growth of 41% per year as estimated by the analysts watching the company. Meanwhile, the rest of the market is forecast to only expand by 15% per annum, which is noticeably less attractive.
With this information, we can see why BASF is trading at such a high P/E compared to the market. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.
The Key Takeaway
Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
As we suspected, our examination of BASF's analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. At this stage investors feel the potential for a deterioration in earnings isn't great enough to justify a lower P/E ratio. Unless these conditions change, they will continue to provide strong support to the share price.
It's always necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with BASF, and understanding these should be part of your investment process.
If you're unsure about the strength of BASF's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
If you decide to trade BASF, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted
Valuation is complex, but we're here to simplify it.
Discover if BASF might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisThis article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
About XTRA:BAS
BASF
Operates as a chemical company worldwide.
Solid track record and good value.
Similar Companies
Market Insights
Weekly Picks

From a “Shark Tank” Snub to an Air Force “Yes”: Why Virtuix at $3.50 May Be the Market’s Most Mispriced AI Story

Mastercard: The Best Dividend Stock You're Ignoring

A Wonderful Business at a Not-So-Wonderful Price

The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect
Recently Updated Narratives

Abitibi Metals’ High-Grade B26 Polymetallic Deposit Trading at a Fraction of Peers, 96% Undervalued?
Zylox-Tonbridge: Early Signs of an Emerging Global Vascular Intervention Platform
Geohan's Growth Outlook Brightens on Expanding Order Book and Easing Cost Pressures
Popular Narratives

Mastercard: The Best Dividend Stock You're Ignoring

Adobe: A Probabilistic Case for Undervaluation
